Evidence map›Paper›PMID 37725309›Full record

ArticleJournal of endocrinological investigation2024

Clinical characteristics, outcomes and risk factors for mortality in hospitalized diabetes and chronic kidney disease patients after COVID-19 infection following widespread vaccination.

Y Zou, C Qin, Q Yang, Y Lang, K Liu, F Yang, X Li, Y Zhao, T Zheng, M Wang and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Y ZouDivision of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China.
C QinDivision of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China.
Q YangDivision of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China.
Y LangDivision of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China.
K LiuDivision of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China.
F YangDepartment of Clinical Medicine, Southwest Medical University, Luzhou, China.
X LiDepartment of Clinical Research Management, West China Hospital of Sichuan University, Chengdu, China.
Y ZhaoDepartment of Clinical Research Management, West China Hospital of Sichuan University, Chengdu, China.
T ZhengInformation Center, West China Hospital of Sichuan University, Chengdu, China.
M WangInformation Center, West China Hospital of Sichuan University, Chengdu, China.
R ShiInformation Center, West China Hospital of Sichuan University, Chengdu, China.
W YangDivision of Project Design and Statistics, West China Hospital of Sichuan University, Chengdu, China.
Y ZhouIntegrated Care Management Center, West China Hospital of Sichuan University, Chengdu, China.
L ChenDepartment of Clinical Research Management, West China Hospital of Sichuan University, Chengdu, China.
Fang LiuDivision of Nephrology, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, China. liufangfh@163.com.ORCID http://orcid.org/0000-0003-1121-3004
Sichuan University · CNSouthwest Medical University · CN

Funding

Health Commission of Sichuan Province Program 21ZD001Key Research and Development Projects of Sichuan Province 2021YFS0368
6 · The paper itself

Abstract

backgroundCOVID-19 poses a significant threat to patients with comorbidities, such as diabetes and chronic kidney disease (CKD). China experienced a nationwide COVID-19 endemic from December 2022 to January 2023, which is the first occurrence of such an outbreak following China's widespread administration of COVID-19 vaccinations.

methodsA total of 338 patients with diabetes and CKD combined with COVID-19 infection between December 7, 2022 and January 31, 2023 were included in this study. The end follow-up date was February 10, 2023. Univariate analysis and multivariate Cox analysis were used to analyze risk factors for death.

resultsDuring the 50-day median follow-up period, 90 patients in the study cohort died, for a mortality rate of 26.63%. The median age of the study cohort was 74 years, with a male predominance of 74%. During hospitalization, 21% of patients had incident AKI, 17% of patients experienced stroke, and 40% of patients experienced respiratory failure. Cox proportional hazard regression showed that older age, a diagnosis of severe or critically severe COVID-19 infection, incident AKI and respiratory failure, higher level of average values of fasting glucose during hospitalization, UA, and total bilirubin were independent risk factors for death in our multivariate model.

conclusionsThese findings highlight the critical importance of identifying and managing comorbid risk factors for COVID-19, especially among the elderly, in order to optimize clinical outcomes, even after COVID-19 vaccination.

Indexed as

Acute Kidney InjuryCOVID-19Diabetes MellitusRenal Insufficiency, ChronicRespiratory InsufficiencyAgedCOVID-19 VaccinesFemaleHumansMaleRisk FactorsVaccinationCOVID-19 VaccinesChronic kidney diseaseCovid-19DiabetesMortality

Identifiers

PMID37725309
OpenAlexW4386845224

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.